Investor News

April 24, 2008 - Preliminary results for year ended 31 December 2007

Cyprotex PLC (LSE:CRX), the drug discovery technology and information company, today reports its preliminary results for the year ended 31 December 2007.

Highlights

Revenues for the year ended 31 December 2007 increased by 3.7% to £3.63 million, against £3.50 million for the comparable period in 2006.
Gross profits for the year rose marginally to £3.00 million from £2.97 million in 2006.
Operating losses for the year were cut by 33% to £496,000 from £741,000 in 2006.
Non-recurring costs of around £80,000, used in defending the group from the attempted requisition, sapped the Group's cash resources during the first half-year.
Despite continued investment, cash-in-hand improved slightly from the low point recorded at the half year to 30 June 2007 of £267,000, to just over £300,000 at the year end.
Commenting on the results, Nikolas Sofronis, Chairman of Cyprotex PLC, said:

“2008 should be the year in which to prove Cyprotex's business plan. The value of the Group's unique technology is clearly recognised through its expanding international customer base. This should bear fruit in the coming months.”

Download Cyprotex Preliminary Results for year ended 31 December 2007

For further information:
Cyprotex PLC
Robert Morrisson Atwater, CEO
Russell Gibbs, CFO
Tel: +44 (0)1625 505 100
ir@cyprotex.com
www.cyprotex.com

Nomura Code Securities Limited:
Charles Walker, Corporate Finance
Tel: +44 (0)20 7776 1200
cew@nomuracode.com
www.nomuracode.com

 
Media Enquires:
WMC Communications
Simon Miller
Tel: +44 (0)20 7930 9030
simon.miller@wmccommunications.com